

Applicants: Haitao Wu, et al.
 Application No.: 10/848,741
 Filed: May 20, 2004
 Docket No.:
 Page 2 of 21


Response to Office Action dated November 19, 2004

IN THE CLAIMS:

This listing of claims replaces all prior versions, and listings, of claims in the application.

Listing of the Claims

1. (Currently Amended) A compound of the formula



wherein:

Y¹, Y², Y³, and Y⁴, are independently on the ortho, meta or para position on the phenyl rings, and are independently hydrogen, alkyl, cycloalkyl, aryl, alkylaryl, arylalkyl, heteroaryl, or an alkyl, cycloalkyl, aryl, alkylaryl, arylalkyl, or heteroaryl group substituted with 1 to 4 hydrophilic groups selected from hydroxy, alkoxy, -C(O)OR⁵, -SOR⁶, -SO₂R⁶, nitro, amido, ureido, carbamato, -SR⁷, -NR⁸R⁹, or polyalkyleneoxide; or a substituent represented by the following formula:



provided that at least one four of Y¹, Y², Y³, and Y⁴ represents formula (2);

X is oxygen or sulfur;

BEST AVAILABLE COPY

Applicants: Hanao Wu, et al.
Application No.: 10/848,741
Filed: May 20, 2004
Docket No.:
Page 3 of 21

Response to Office Action dated November 19, 2004

$R^1, R^2, R^5, R^6, R^7, R^8$, and R^9 are independently selected from hydrogen and C_1 to C_4 alkyl;

Z is a carborane cluster comprising at least two carbon atoms and at least three boron atoms, or at least one carbon atom and at least five boron atoms, within a cage structure;

r is 0 or an integer from 1 to 20;

W^1, W^2, W^3 , and W^4 are hydrophilic groups independently selected from hydroxy, alkoxy, $-C(O)OR^5$, $-SOR^6$, $-SO_2R^6$, nitro, amido, ureido, carbamato, $-SR^7$, $-NR^8R^9$, or polyalkylene oxide;

a, b, c , and d independently represent an integer from 1 to 4;

m, n, p , and q are independently 0 or an integer from 1 to 4;

provided that at least one of m, n, p , and q is not zero, and each of the sums $a + m$, $b + n$, $c + p$, and $d + q$, independently represents an integer from 1 to 5; and

M is either two hydrogen ions; a single monovalent metal ion; two monovalent metal ions; a divalent metal ion; a trivalent metal ion; a tetravalent metal ion; a pentavalent metal ion; a hexavalent metal ion; a radioactive metal ion useful in radioisotope-mediated radiation therapy or imageable by single photon emission computed tomography (SPECT) or positron emission tomography (PET); a paramagnetic metal ion detectable by magnetic resonance imaging (MRI); a metal ion suitable for boron neutron capture therapy (BNCT) or photodynamic therapy (PDT); or a combination thereof; wherein the porphyrin metal complex derived from when M is a single monovalent metal ion, a porphyrin-metal complex is produced which is charge-balanced by a counter cation, and the porphyrin metal complex derived from when M is a trivalent, tetravalent, pentavalent, or hexavalent metal ion, a porphyrin-metal complex is produced which is charge-balanced by an appropriate number of counter anions, dianions, or trianions.

Applicants: Haitao Wu, et al.
Application No.: 10/848,741
Filed: May 20, 2004
Docket No.:
Page 4 of 21

Response to Office Action dated November 19, 2004

2. (Original) The compound according to claim 1 wherein Z is selected from the carboranes -C₂HB₉H₁₀ or -C₂HB₁₀H₁₀, wherein -C₂HB₉H₁₀ is *nido* ortho-, meta-, or para-carborane, and -C₂HB₁₀H₁₀ is *clos* ortho-, meta-, or para-carborane.
3. (Original) The compound according to claim 1, wherein M is vanadium, manganese, iron, ruthenium, technetium, chromium, platinum, cobalt, nickel, copper, zinc, germanium, indium, tin, yttrium, gold, barium, tungsten, or gadolinium.
4. (Currently Amended) The compound according to claim 1 wherein a, b, c, and d are 1, and Y¹, Y², Y³, and Y⁴ are represented by ~~X-(CR¹R²)_r-Z~~
~~(2)-X-(CR¹R²)_r-Z (2)~~.
5. (Original) The compound according to claim 4 wherein Z is selected from the carboranes -C₂HB₉H₁₀ or -C₂HB₁₀H₁₀, wherein -C₂HB₉H₁₀ is *nido* ortho-, meta-, or para-carborane, and -C₂HB₁₀H₁₀ is *clos* ortho-, meta-, or para-carborane.
6. (Original) The compound according to claim 5, wherein M is vanadium, manganese, iron, ruthenium, technetium, chromium, platinum, cobalt, nickel, copper, zinc, germanium, indium, tin, yttrium, gold, barium, tungsten, or gadolinium.
7. (Original) The compound according to claim 6, wherein X is O; R¹ and R² are H; r is 1; and m, n, p and q are each 1.
8. (Original) The compound according to claim 7 wherein Y¹, Y², Y³, and Y⁴ are in the para position on the phenyl ring, and W¹, W², W³, and W⁴ are independently, hydroxy or alkoxy groups.
9. (Original) The compound according to claim 8 wherein W¹, W², W³, and W⁴ are alkoxy groups.
10. (Original) The compound according to claim 9 wherein the alkoxy groups are methoxy groups.

Applicants: Haitao Wu, et al.
Application No.: 10/848,741
Filed: May 20, 2004
Docket No.:
Page 5 of 21

Response to Office Action dated November 19, 2004

11. (Original) The compound according to claim 10 wherein the methoxy groups are in the meta position of the phenyl ring.
12. (Original) The compound according to claim 8 wherein W^1 , W^2 , W^3 , and W^4 are hydroxy groups.
13. (Original) The compound according to claim 10 wherein the hydroxy groups are in the meta position of the phenyl ring.
14. (Currently Amended) The A method of imaging a tumor and surrounding tissue in a subject comprising the administration to the subject of a composition comprising a compound according to claim 1; and the imaging of said subject by a method selected from magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), or positron emission tomography (PET) methods.
15. (Currently Amended) A method of imaging a tumor and surrounding tissue in a subject comprising the administration to the subject of a composition comprising a compound according to claim 11; and the imaging of said subject by a method selected from magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), or positron emission tomography (PET) methods.
16. (Currently Amended) A method of imaging a tumor and surrounding tissue in a subject comprising the administration to the subject of a composition comprising a compound according to claim 13; and the imaging of said subject by a method selected from magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), or positron emission tomography (PET) methods.
17. (Cancelled)
18. (Original) A method of bimodal cancer treatment in a subject comprising the administration to the subject of a composition comprising a compound according to claim 1; and the irradiation of said subject.

Applicants: Hartao Wu, et al.
Application No.: 10/848,741
Filed: May 20, 2004
Docket No.:
Page 6 of 21


Response to Office Action dated November 19, 2004

19. (Original) A method of bimodal cancer treatment in a subject comprising the administration to the subject of a composition comprising a compound according to claim 11; and the irradiation of said subject.
20. (Original) A method of bimodal cancer treatment in a subject comprising the administration to the subject of a composition comprising a compound according to claim 13; and the irradiation of said subject.
21. (Original) The method according to any of claims 18, 19, or 20 wherein said irradiation is by a method utilizing thermal or epithermal neutrons, or laser red light.
22. (Original) The method according to any of claims 18, 19, or 20 wherein said bimodal cancer treatment comprises boron neutron capture therapy (BNCT).
23. (Original) The method according to any of claims 18, 19, or 20 wherein said bimodal cancer treatment comprises photodynamic therapy (PDT).
24. (Original) The method according to any of claims 18, 19, or 20 wherein said bimodal cancer treatment utilizes single photon emission computed tomography (SPECT) or positron emission tomography (PET) wherein M is a SPECT- and/or PET-imageable radioactive metal ion.
25. (Original) The method according to any of claims 18, 19, or 20 wherein said bimodal cancer treatment utilizes magnetic resonance imaging (MRI) wherein M is a paramagnetic metal ion.
- 26-27. (Cancelled)

Applicants: Haitao Wu, et al.
 Application No.: 10/848,741
 Filed: May 20, 2004
 Docket No.:
Page 7 of 21


Response to Office Action dated November 19, 2004

28. (New) A compound of the formula



wherein:

Y^1 , Y^2 , Y^3 , and Y^4 , are independently on the ortho, meta or para position on the phenyl rings, and are independently hydrogen, alkyl, cycloalkyl, aryl, alkylaryl, arylalkyl, heteroaryl, or an alkyl, cycloalkyl, aryl, alkylaryl, arylalkyl, or heteroaryl group substituted with 1 to 4 hydrophilic groups selected from hydroxy, alkoxy, $-C(O)OR^5$, $-SOR^6$, $-SO_2R^6$, nitro, amido, ureido, carbamato, $-SR^7$, $-NR^8R^9$, or poly-alkyleneoxide; or a substituent represented by the following formula:



provided that at least four of Y^1 , Y^2 , Y^3 , and Y^4 represents formula (2);

X is oxygen or sulfur;

R^1 , R^2 , R^5 , R^6 , R^7 , R^8 , and R^9 are independently selected from hydrogen and C_1 to C_4 alkyl;

Z is a carborane cluster comprising at least two carbon atoms and at least three boron

Applicants: Haitao Wu, et al.
Application No.: 10/848,741
Filed: May 20, 2004
Docket No.:
Page 8 of 21

Response to Office Action dated November 19, 2004

atoms, or at least one carbon atom and at least five boron atoms, within a cage structure;

r is 0 or an integer from 1 to 20;

W^1 , W^2 , W^3 , and W^4 are hydrophilic groups independently selected from hydroxy, alkoxy, $-C(O)OR^5$, $-SOR^6$, $-SO_2R^6$, nitro, amido, ureido, carbamato, $-SR^7$, $-NR^8R^9$, or polyalkylene oxide;

a, b, c, and d independently represent an integer from 1 to 4;

m, n, p, and q are independently 0 or an integer from 1 to 4;

provided that at least one of m, n, p, and q is not zero, and each of the sums a + m, b + n, c + p, and d + q, independently represents an integer from 1 to 5; and


M is a trivalent, tetravalent, pentavalent, or hexavalent metal ion, thereby producing a porphyrin-metal complex; and

wherein the porphyrin-metal complex is charge-balanced by one or more porphyrin compounds containing a divalent negative charge.

29. (New) The compound according to claim 28 wherein said one or more porphyrin compounds containing a divalent negative charge are represented by the formula

Applicants: Martao Wu, et al.
 Application No.: 10/848,741
 Filed: May 20, 2004
 Docket No.:
Page 9 of 21

Response to Office Action dated November 19, 2004



wherein:

Y¹, Y², Y³, and Y⁴, are independently on the ortho, meta or para position on the phenyl rings, and are independently hydrogen, alkyl, cycloalkyl, aryl, alkylaryl, arylalkyl, heteroaryl, or an alkyl, cycloalkyl, aryl, alkylaryl, arylalkyl, or heteroaryl group substituted with 1 to 4 hydrophilic groups selected from hydroxy, alkoxy, -C(O)OR⁵, -SOR⁶, -SO₂R⁶, nitro, amido, ureido, carbamato, -SR⁷, -NR⁸R⁹, or polyalkyleneoxide; or a substituent represented by the following formula:



provided that at least four of Y¹, Y², Y³, and Y⁴ represents formula (2);

X is oxygen or sulfur;

R¹, R², R⁵, R⁶, R⁷, R⁸, and R⁹ are independently selected from hydrogen and C₁ to C₄ alkyl;

Z is a carborane cluster comprising at least two carbon atoms and at least three boron atoms, or at least one carbon atom and at least five boron atoms, within a cage structure;

Applicants: Haitao Wu, et al.
Application No.: 10/848,741
Filed: May 20, 2004
Docket No.:
Page 10 of 21

Response to Office Action dated November 19, 2004

r is 0 or an integer from 1 to 20;

W^1 , W^2 , W^3 , and W^4 are hydrophilic groups independently selected from hydroxy, alkoxy, $-C(O)OR^5$, $-SOR^6$, $-SO_2R^6$, nitro, amido, ureido, carbamato, $-SR^7$, $-NR^8R^9$, or polyalkylene oxide;

a, b, c, and d independently represent an integer from 1 to 4;

m, n, p, and q are independently 0 or an integer from 1 to 4; and

provided that at least one of m, n, p, and q is not zero, and each of the sums a + m, b + n, c + p, and d + q, independently represents an integer from 1 to 5.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.